{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-24-000194","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.733696+00:00","generated_at":"2026-05-30T03:45:30.630156+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GoodRx Q3 2024 revenue $195.3M, net income $4.0M, Adjusted EBITDA $65.0M","bullets":["Revenue and Adjusted Revenue both $195.3 million for Q3 2024.","Net income of $4.0 million (2.0% margin); Adjusted Net Income $31.9 million (16.4% margin).","Adjusted EBITDA $65.0 million (33.3% margin); operating cash flow $86.9 million.","Exited Q3 with over 7 million consumers of prescription-related offerings.","Expects ~20% YoY growth in pharma manufacturer solutions for Q4 2024 and 20%+ for FY 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-24-000194","json":"https://secwatch.observer/filing/0001809519-24-000194.json","markdown":"https://secwatch.observer/filing/0001809519-24-000194.md","text":"https://secwatch.observer/filing/0001809519-24-000194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000194/0001809519-24-000194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000194/gdrx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:45:30.630156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}